ESR1 and neoplasm: Despite extensive use of anti-estrogen drugs like tamoxifen, there is, as of yet, no biomarker to assist the clinician in selecting patients who have a high probability of benefit from tamoxifen besides the measurement of ER and PR expression in the tumor tissue.